A study evaluating effect of Bruton's tyrosine kinase and Phosphoinositide 3 kinase inhibitors on opportunistic infections in patients with hematologic malignancies.
Latest Information Update: 24 Oct 2017
Price :
$35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Duvelisib (Primary) ; Ibrutinib (Primary) ; Idelalisib (Primary) ; Spebrutinib (Primary) ; Umbralisib (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 24 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017